Press Release / Media Release

Panacea Biotec Ltd. has delighted to announce that its abbreviated new drug application (ANDA) submitted under section 505(j) of the Federal Food, Drug and Cosmetic Act (FD&C Act) for Paclitaxel Protein Bound Particles for injectable Suspension, 100mg/vial has been accepted for filing by the U.S. Food and Drug Administration (FDA).

A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Pdf Link: Press Release / Media Release

Source : BSE -

Published on November 30, 2017


This article is closed for comments.
Please Email the Editor